Resmed (ASX:RMD) reported Friday fiscal second-quarter earnings of $2.43 per diluted share on a non-GAAP basis, up from $1.88 per diluted share a year earlier.

Analysts polled by Visible Alpha expected $2.32 per diluted share.

Revenue for the three months ended Dec. 31, 2024, rose 10% to $1.28 billion from $1.16 billion a year earlier. Analysts surveyed by Visible Alpha expected $1.27 billion.

The board declared a quarterly cash dividend of $0.53 per share, with a record date of Feb. 13, payable on March 20. This is up from the previously reported period's dividend of $0.48.